This neutral lipid, used in commercially marketed products, is more than 99 per cent pure; offers high batch-to-batch consistency and is scalable under commercial GMP.
To meet the high demand for lipids, a key component of mRNA-based vaccines and therapeutics, MilliporeSigma has launched a new, high-purity synthetic cholesterol product, nine months ahead of schedule.